Artificial intelligence (AI) provider Lunit recently received preliminary approval from the Korea Exchange for initial public offering on the KOSDAQ market.
The company will submit a registration statement within the first half of 2022, while NH Investment & Securities will underwrite the offering. Upon listing, Lunit will use secured funding for research and development of its AI products and global market development.
Founded in 2013, Lunit has supplied products to about 600 medical sites in more than 40 countries worldwide. This has been bolstered by partnerships with global medical device companies such as GE Healthcare, Philips, and Fujifilm.
In addition, the company is also signing an exclusive business contract with Guardant Health for its biomarker business.
